CSTL Castle Biosciences

Castle Biosciences Honored with Top Workplaces Awards

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2024 Top Workplaces program, including: a third consecutive Arizona Top Workplaces award from AZ Central, the digital home of The Arizona Republic newspaper; a second consecutive national Healthcare Industry Top Workplaces award; and five Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values.

“We are incredibly honored to have been named a Top Workplace in Arizona for the third year in a row in addition to being twice-recognized as a national Top Workplace in the Healthcare Industry among so many distinguished companies,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Receiving multiple, consecutive Top Workplace designations holds immense significance, as they stem directly from feedback received from our Castle team members. These achievements exemplify our steadfast commitment to fostering an exceptional, people-first workplace culture that inspires our team members and fuels our shared passion for improving patient care.”

Now in its 17th year, the surveys and celebrates people-first organizations nationally and across 60 regional markets. Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling “respected & supported,” “enabled to grow” and “empowered to execute,” among others. Additionally, it measures 15 culture drivers that are indicative of successful organizations, such as alignment, execution and connection.

Earlier this year, Castle earned a national Top Workplaces award (also for the third consecutive year) and also received five Top Workplaces Culture Excellence Awards (multiple years running) for continued excellence in the following areas of its company culture:

  • Innovation (2022, 2023, 2024), for creating a culture where new ideas are encouraged, which helps employees reach their full potential and benefits performance.
  • Work-Life Flexibility (2023, 2024), for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
  • Compensation & Benefits (2022, 2023, 2024), for providing packages employees believe are fair for the work being done and compared to others in the industry.
  • Leadership (2022, 2023, 2024), for organizational leaders who inspire confidence in employees and the company direction, listening to what matters most to employees and using that insight in decision making.
  • Purpose & Values (2022, 2023, 2024), for successfully communicating the company mission and integrating those aspirations into the culture.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage chief executive officer. “In today's market, leaders must ensure they’re allowing employees to have a voice and be heard; that's paramount. Top Workplaces do this, and it pays dividends.”

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to work together.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

EN
11/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and ...

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide pati...

 PRESS RELEASE

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

 PRESS RELEASE

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch